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Introduction
============

We commend Dinh et al. for their early and informative work describing the radiation therapy policy and procedural changes of the University of Washington (UW) in the Seattle-Puget Sound region during the initial stages of the U.S. COVID-19 outbreak \[[@REF1]\]. Their proactive policies provided vital pre-emptive guidance to our department and radiation oncology departments across the country. After Seattle, New York City became one of the next major cities to be affected and has quickly emerged as the epicenter of the COVID-19 pandemic in the United States, with 76,876 confirmed cases as of April 7, 2020. 

The New York Proton Center (NYPC) is a freestanding facility located in Manhattan. Currently, five NYPC-employed radiation oncologists and 19 partner radiation oncologists from three consortium institutions (Memorial Sloan Kettering Cancer Center, Montefiore Health System, and Mount Sinai Health System) treat 80-85 patients/day. Since the first reported COVID-19 case in New York on March 1, 2020, the center has faced many challenges maintaining safe delivery of patient care. As the impact on radiation oncology patients of the COVID-19 pandemic is yet to be quantified, we describe some of our challenges and institutional policies aimed at mitigating the spread of COVID-19 amongst our patients and detail the proportion of patients affected during the initial one-month interval.

Technical report
================

Similar to the UW, we instituted policies to minimize risks to patients, including providing patient education materials; completing daily symptom screenings of patients and close contacts; implementing rigorous sanitization measures; deferring treatment of indolent diseases; instituting telemedicine appointments, virtual meetings, restricting visitors, spacing-out treatment times, and closing patient waiting rooms. Patients in subacute care or nursing facilities were no longer eligible for treatment until discharged and we utilized hypofractionation to shorten treatment schedules per expert-consensus, when feasible \[[@REF2]-[@REF5]\]. Lastly, we began prospectively monitoring each patient on treatment and those expected to initiate treatment for new symptoms, date of onset, possible sick contacts, and COVID-19 test results. 

Based on increasing personnel losses due to illness and the need to optimize safety for all of our patients and staff, we deferred treatment of COVID-19-positive patients. By March 19, 2020, we instituted a new patient policy requiring symptomatic patients to obtain a negative COVID-19 test before treatment could resume/initiate, and COVID-19-positive patients must be serologically cleared prior to resuming. Patients with high-risk exposure are immediately quarantined and must either remain asymptomatic for a minimum of 10 days prior to treatment (i.e., two standard deviations of the average incubation period) and/or obtain a negative COVID-19 test, if available. Treatment starts are delayed to accommodate these requirements unless urgent circumstances are present, determined on a case-by-case basis.

Institutional Review Board approval was obtained for the evaluation of the following patient-level data. From March 1, 2020 to March 31, 2020, 137 patients received, or underwent simulation to receive, radiotherapy at NYPC. Of these 137 patients, 15 (11%) were monitored for concerning symptoms or high-risk exposures (Table [1](#TAB1){ref-type="table"}). Alterations in treatment plans due to COVID-19 workup were necessary in 11 (8%) patients. The remaining four (3%) patients were monitored due to high-risk exposures (e.g., same household family member COVID-19 positive) but adequately evaluated and cleared through short-term quarantine, symptom evaluation, and/or negative COVID testing without impacting their treatment course. Of the 11 affected patients, seven were cleared and rescheduled for treatment, resulting in a median delay of seven days (range 2-32 days). Four patients, however, are indefinitely delayed or have stopped treatment entirely, including three confirmed COVID-19 infections in total. Of these three, one patient expired due to COVID-19 illness and one has initiated comfort care measures.

###### Patient characteristics.

CTX, chemotherapy; HN, head and neck; COVID, Coronavirus disease 2019; GI, gastrointestinal

  --------- ------------- ---------- ---------------- -------------- --------------------------------------------- ------------------------------------------------------------------------------------------ ----------------------------
  Patient   Age (years)   Site       Concurrent CTX   On-treatment   Symptoms/Risk factors                         Outcome                                                                                    Days missed or delayed
  1         81            HN         No               No             Asymptomatic Elderly                          Quarantine delayed treatment start                                                         19 days
  2         86            HN         No               No             Fever, headache                               COVID+ admitted to hospital, patient expired                                               Indefinitely
  3         57            HN         No               No             Fever                                         COVID- delayed treatment start                                                             7 days
  4         59            HN         No               No             Cough, dyspnea, sore throat                   COVID indeterminate quarantined 14 days without symptoms, plan to proceed with treatment   0 days
  5         66            HN         Yes              Yes            Fever, cough                                  COVID- treatment interrupted                                                               5 days
  6         85            HN         No               Yes            Fever, cough, dyspnea                         COVID+ admitted to hospital, comfort care measures initiated                               Indefinitely
  7         65            HN         Yes              Yes            Fever, cough                                  COVID- admitted for 4 days, treated for pneumonia                                          4 days
  8         6             Brain      Yes              No             Asymptomatic indirect exposure                Quarantine resolved before treatment start                                                 0 days
  9         7             Brain      No               No             Fever admitted due to other medical reasons   Family refused COVID testing delayed until discharged                                      2 days
  10        70            Brain      Yes              No             Asymptomatic indirect exposure                Quarantine                                                                                 0 days
  11        1             Sarcoma    Yes              No             Asymptomatic parents COVID+                   Quarantine delayed treatment start                                                         32 days
  12        20            Sarcoma    Yes              Yes            Asymptomatic father is COVID+                 Deferred COVID testing treatment interrupted                                               Indefinitely (ended early)
  13        67            Thoracic   Yes              Yes            Cough, dyspnea                                COVID+ admitted to hospital, treatment interrupted                                         Indefinitely
  14        46            Breast     No               Yes            Asymptomatic indirect exposure                Quarantine                                                                                 0 days
  15        67            GI         No               No             Asymptomatic wife is COVID+                   Quarantine delayed treatment start                                                         20 days
  --------- ------------- ---------- ---------------- -------------- --------------------------------------------- ------------------------------------------------------------------------------------------ ----------------------------

The majority of patients who required monitoring had not yet started treatment (9/15, 60%). The most common scenario was the development of new symptoms prior to simulation. Of these patients, all but one has since been cleared and rescheduled, resulting in a median delay of 4.5 days (range 0-32 days). The one patient not yet cleared was confirmed COVID-19 positive and treatment remains on hold. Of the six patients on-treatment requiring further evaluation (40%), five suffered treatment interruptions, three of whom are now rescheduled to resume after a median delay of four days (range 0-5 days). Three remain indefinitely delayed, including two who were confirmed COVID-19 positive and one who terminated treatment early with two fractions remaining.

Discussion
==========

Given the proportion of patients who developed symptoms prior to initiating treatment, our experience supports the recommendation for rigorous screening in advance of treatment initiation as well as between appointments (e.g., when simulation and treatment start are \>1 week apart). In addition, with increasing reports of asymptomatic transmission, routine inspection of lung imaging on simulation and cone-beam CT images is strongly encouraged \[[@REF6]-[@REF7]\]. Patients on-treatment were less commonly affected, which may be due to greater precautions to self-quarantine. However, on-treatment patients may also be more difficult to assess given ongoing treatment-related side effects. For example, some of the most common COVID-19 symptoms occur frequently among cancer patients receiving radiotherapy, including sore throat, cough, shortness of breath, and fatigue. Given the difficulty assessing patients on-treatment for COVID-19 related symptoms, we recommend close scrutiny of any new or ambiguous complaints and a low-threshold for viral testing.

We also have an average of five to seven pediatric patients on-treatment requiring daily sedation with anesthesia. UW's anesthesia policy included airborne precautions due to reports of aerosol transmission \[[@REF8]\]. NYPC instituted a policy on March 30, 2020 requiring COVID-19 testing before simulation, again prior to the first fraction, and weekly thereafter while on-treatment to further maximize safety. For patient comfort, the weekly diagnostic nasal swabs are obtained while the patient is under general anesthesia, typically after treatment is completed each Friday to allow test results to return before the subsequent treatment on Monday. 

Lastly, we assessed the utilization and sanitization procedure of our respiratory motion management system, SDX (DYN'R, Miami, FL). Similar to UW and Thomas Jefferson University, we developed a new and stringent disinfecting protocol and encouraged the use of abdominal compression and proton repainting techniques over breath-hold whenever clinically possible \[[@REF9]-[@REF10]\]. NYPC now requires manufacturer-recommended monthly full-system cleaning after every patient use which typically takes 10 min to perform. Prior to the COVID-19 outbreak, NYPC treated on average four SDX cases per day. Over the last two weeks prior to publication, only two patients remain on treatment using SDX and no new cases are currently under treatment planning. 

Conclusions
===========

Despite the early implementation of measures described by the UW radiation oncology department as well as our own highly conservative policies, NYPC still had 11% of patients affected, including 3% confirmed positive for COVID-19 within the first month and one patient death. All of the delays at NYPC occurred in the second half of the month, suggesting other cities should expect and prepare for an acceleration of patient events near their projected regional pandemic peak. While most interruptions were of short duration and did not appear clinically meaningful, implementation of these strict policies likely mitigated further patient exposure and more significant treatment delays. We plan to continue to enforce and reassess our policies throughout the pandemic to balance patient safety and optimal treatment delivery.
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